Cytokinetics, Incorporated (CYTK) Financials

NASDAQ:CYTK

Market Cap

3.16B

Total Revenue

94.59M

Gross Profit

-146.22M

Operating Income

-324.20M

Net Income

-402.55M

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	30,648,000	46,940,000	28,658,000	106,407,000	13,368,000	31,501,000	26,868,000	55,828,000	70,428,000	94,588,000
costOfRevenue	49,450,000	44,426,000	46,398,000	59,897,000	90,296,000	89,135,000	86,125,000	96,951,000	159,938,000	240,813,000
grossProfit	-18,802,000	2,514,000	-17,740,000	46,510,000	-76,928,000	-57,634,000	-59,257,000	-41,123,000	-89,510,000	-146,225,000
researchAndDevelopmentExpenses	49,450,000	44,426,000	46,398,000	59,897,000	90,296,000	89,135,000	86,125,000	96,951,000	159,938,000	6,588,000
sellingAndMarketingExpenses	--	--	--	--	--	--	--	--	--	--
generalAndAdministrativeExpenses	15,092,000	17,268,000	19,667,000	27,823,000	36,468,000	31,282,000	39,610,000	52,820,000	96,803,000	177,977,000
sellingGeneralAndAdministrativeExpenses	15,092,000	17,268,000	19,667,000	27,823,000	36,468,000	31,282,000	39,610,000	52,820,000	96,803,000	177,977,000
operatingExpenses	15,092,000	17,268,000	19,667,000	27,823,000	36,468,000	31,282,000	39,610,000	52,820,000	96,803,000	177,977,000
operatingIncome	-33,894,000	-14,754,000	-37,407,000	18,687,000	-113,396,000	-88,916,000	-98,867,000	-93,943,000	-186,313,000	-324,202,000
totalOtherIncomeExpensesNet	177,000	108,000	-94,000	-2,234,000	-14,394,000	-17,373,000	-22,825,000	-33,347,000	-29,001,000	-64,753,000
ebitda	-33,894,000	-14,754,000	-37,407,000	18,687,000	-110,794,000	-84,725,000	-93,039,000	-88,614,000	-185,982,000	-312,860,000
depreciationAndAmortization	433,000	490,000	589,000	741,000	1,920,000	1,239,000	5,828,000	5,329,000	331,000	11,342,000
interestIncome	177,000	108,000	-94,000	-2,234,000	2,602,000	4,191,000	4,535,000	5,329,000	331,000	11,342,000
interestExpense	-177,000	-108,000	94,000	2,234,000	16,996,000	21,564,000	27,360,000	38,676,000	29,332,000	51,156,000
incomeBeforeTax	-33,717,000	-14,646,000	-37,501,000	16,453,000	-127,790,000	-106,289,000	-121,692,000	-127,290,000	-215,314,000	-388,955,000
incomeTaxExpense	-433,000	-490,000	-589,000	-741,000	682,000	4,191,000	27,360,000	36,845,000	27,056,000	13,597,000
netIncome	-33,717,000	-14,646,000	-37,501,000	16,453,000	-127,790,000	-106,289,000	-149,052,000	-164,135,000	-242,370,000	-402,552,000
eps	-1.24	-0.41	-0.97	0.41	-2.59	-1.95	-2.59	-2.54	-3.15	-4.48
epsdiluted	-1.24	-0.41	-0.97	0.39	-2.59	-1.95	-2.59	-2.54	-3.15	-4.48
weightedAverageShsOut	27,275,000	35,709,000	38,814,000	39,943,000	49,404,000	54,420,000	57,575,000	64,524,000	76,886,000	89,825,000
weightedAverageShsOutDil	27,275,000	35,709,000	38,814,000	42,561,000	49,404,000	54,420,000	57,575,000	64,524,000	76,886,000	89,825,000
costAndExpenses	64,542,000	61,694,000	66,065,000	87,720,000	126,764,000	120,417,000	125,735,000	149,771,000	256,741,000	418,790,000
otherExpenses	47,431,000	24,888,000	31,733,000	58,655,000	--	--	-86,125,000	-96,951,000	-159,938,000	-6,588,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

South San Francisco, CA, US

Website

cytokinetics.com

CEO

Mr. Robert I. Blum

Employees

409

About the Company

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.